In the world of pharmaceutical distribution, product recalls aren’t an occasional inconvenience—they’re an operational reality. And when they occur, the expectations on wholesale dealers are high. The MHRA’s guidance is clear: distributors sit at a pivotal junction in the recall process, and their preparedness can determine whether a quality issue stays contained or becomes a national problem.
When quality issues arise in the lifecycle of a medicinal product, the consequences extend far beyond the pharmacy shelf. The MHRA’s latest 2026 guidance on defective medicinal products offers a comprehensive roadmap for managing these events with rigour, transparency, and patient safety at the centre.
There is a hard stop to the change process, from 1st April the system will be operable, and the products registered at that point will decide the fees payable for 2026/27. So, there are a number of actions manufacturers and UKRPs will need to consider.
To place medical devices onto the UK market manufacturers must register with the MHRA and register all relevant products, registration must be active when each batch of product is placed on the market. For manufacturers based outside the Uk this is done via the UKRP.
Almost is one of the longest words in the English dictionary where all its letters are in alphabetical order which got us thinking, how could you use almost as an acronym to ensure compliance with GDP and not just almost compliant.
Pharmacists need to check their Professional Indemnity Insurance to ensure that it covers them for the services they are providing, and to ensure that the level of cover is sufficient.
